Literature DB >> 3962705

To keep the alcoholic in out-patient treatment. A differentiated approach through treatment contracts.

A Ojehagen, M Berglund.   

Abstract

Eighty-two alcoholics were offered a 2-year out-patient programme characterized by stressing the patients' own decisions both in joining the programme and in the choice of objectives and methods, by repeated feedbacks through treatment evaluations, and by relapse prevention. The 58 patients who accepted were more often married than the others. All but eight completed the programme. The most important treatment components were ranked by the patients. Individual counselling was ranked highest, followed by evaluations of contract with therapist, disulfiram and biofeedback by means of gamma-GT. Patients with alcohol dependence more often preferred instrumental components, such as disulfiram and gamma-GT, while the others more often preferred psychological components, such as individual counselling and contract evaluations. Preference of psychological components was not found to be related to degree of personality disturbances. It is suggested that to effectively keep the patients in treatment in the present programme depends on the combination of patients' active engagement, continuous feedback and individualized treatment objectives.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3962705     DOI: 10.1111/j.1600-0447.1986.tb02669.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  2 in total

1.  Acceptance, attrition, and outcome in an outpatient treatment programme for alcoholics. A comparison between a randomized and a non-randomized process-outcome study.

Authors:  A Ojehagen; M Berglund
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

2.  Partial ALDH inhibition to facilitate controlled drinking rather than abstinence has already been tried and it works.

Authors:  Colin Brewer
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-03       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.